A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis

Li, Rongkang; Chen, Wenkang; Lu, Chong; Li, Xinji; Chen, Xuan; Huang, Guoxin; Wen, Zhenyu; Li, Hang; Tao, Lingzhi; Hu, Yimin; Zhao, Zhengping; Chen, Zebo; Ni, Liangchao; Lai, Yongqing

doi:10.3389/fonc.2022.1076303

Cited by 3 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The AUC of a four-miRNA panel for RCC diagnosis containing miR-1-3p, miR-155-5p, miR-200b-3p, and miR-224-5p was 0.903 (95% CI 0.847–0.944; p < 0.001; sensitivity = 75.61%; specificity = 93.67%) [ 44 ]. Similarly, the AUC of another four-miRNA panel, containing miR-18a-5p, miR-138-5p, miR-141-3p, and miR-181b-5p, was 0.908 (95% CI 0.852–0.948; sensitivity = 80.77%, specificity = 88.89%) [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

A serum panel of three microRNAs may serve as possible biomarkers for kidney renal clear cell carcinoma

Wen,

Li,

Zhao

et al. 2024

Cancer Cell Int

Self Cite

View full text Add to dashboard Cite

Background Although non-invasive radiological techniques are widely applied in kidney renal clear cell carcinoma (KIRC) diagnosis, more than 50% of KIRCs are detected incidentally during the diagnostic procedures to identify renal cell carcinoma (RCC). Thus, sensitive and accurate KIRC diagnostic methods are required. Therefore, in this study, we aimed to identify KIRC-associated microRNAs (miRNAs). Methods This three-phase study included 224 participants (112 each of patients with KIRC and healthy controls (NCs)). RT-qPCR was used to evaluate miRNA expression in KIRC and NC samples. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were used to predict the usefulness of serum miRNAs in KIRC diagnosis. In addition, we performed survival and bioinformatics analyses. Results We found that miR-1-3p, miR-129-5p, miR-146b-5p, miR-187-3p, and miR-200a-3p were significantly differentially expressed in patients with KIRC. A panel consisting of three miRNAs (miR-1-3p, miR-129-5p, and miR-146b-5p) had an AUC of 0.895, ranging from 0.848 to 0.942. In addition, using the GEPIA database, we found that the miRNAs were associated with CREB5. According to the survival analysis, miR-146b-5p overexpression was indicative of a poorer prognosis in patients with KIRC. Conclusions The identified three-miRNA panel could serve as a non-invasive indicator for KIRC and CREB5 as a potential target gene for KIRC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

A serum panel of three microRNAs may serve as possible biomarkers for kidney renal clear cell carcinoma

Wen,

Li,

Zhao

et al. 2024

Cancer Cell Int

Self Cite

View full text Add to dashboard Cite

show abstract

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Hayashi,

Millen,

Ramos

et al. 2024

Molecular Oncology

View full text Add to dashboard Cite

As cutting‐edge technologies applied for the study of body fluid molecular biomarkers are continuously evolving, clinical applications of these biomarkers improve. Diverse forms of circulating molecular biomarkers have been described, including cell‐free DNA (cfDNA), circulating tumor cells (CTCs), and cell‐free microRNAs (cfmiRs), although unresolved issues remain in their applicability, specificity, sensitivity, and reproducibility. Translational studies demonstrating the clinical utility and importance of cfmiRs in multiple cancers have significantly increased. This review aims to summarize the last 5 years of translational cancer research in the field of cfmiRs and their potential clinical applications to diagnosis, prognosis, and monitoring disease recurrence or treatment responses with a focus on solid tumors. PubMed was utilized for the literature search, following rigorous exclusion criteria for studies based on tumor types, patient sample size, and clinical applications. A total of 136 studies on cfmiRs in different solid tumors were identified and divided based on tumor types, organ sites, number of cfmiRs found, methodology, and types of biofluids analyzed. This comprehensive review emphasizes clinical applications of cfmiRs and summarizes underserved areas where more research and validations are needed.

show abstract

Research progress on miR-124-3p in the field of kidney disease

Chen,

Wang,

Zhang

et al. 2024

BMC Nephrol

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are 18–25 nucleotides long, single-stranded, non-coding RNA molecules that regulate gene expression. They play a crucial role in maintaining normal cellular functions and homeostasis in organisms. Studies have shown that miR-124-3p is highly expressed in brain tissue and plays a significant role in nervous system development. It is also described as a tumor suppressor, regulating biological processes like cancer cell proliferation, apoptosis, migration, and invasion by controlling multiple downstream target genes. miR-124-3p has been found to be involved in the progression of various kidney diseases, including diabetic kidney disease, calcium oxalate kidney stones, acute kidney injury, lupus nephritis, and renal interstitial fibrosis. It mediates these processes through mechanisms like oxidative stress, inflammation, autophagy, and ferroptosis. To lay the foundation for future therapeutic strategies, this research group reviewed recent studies on the functional roles of miR-124-3p in renal diseases and the regulation of its downstream target genes. Additionally, the feasibility, limitations, and potential application of miR-124-3p as a diagnostic biomarker and therapeutic target were thoroughly investigated.

show abstract

A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis

Cited by 3 publications

References 58 publications

A serum panel of three microRNAs may serve as possible biomarkers for kidney renal clear cell carcinoma

A serum panel of three microRNAs may serve as possible biomarkers for kidney renal clear cell carcinoma

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Research progress on miR-124-3p in the field of kidney disease

Contact Info

Product

Resources

About